Information between 2nd September 2024 - 12th September 2024
Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.
Non-Departmental Publications - Transparency |
---|
Sep. 10 2024
NHS Blood and Transplant Source Page: NHS Blood and Transplant annual report and accounts: 2023 to 2024 Document: (PDF) Transparency Found: Stem cell transplantation plays a vital role in treating certain blood and metabolic conditions, including |
Sep. 10 2024
NHS Blood and Transplant Source Page: NHS Blood and Transplant annual report and accounts: 2023 to 2024 Document: (PDF) Transparency Found: Stem cell transplantation plays a vital role in treating certain blood and metabolic conditions, including |
Arms Length Bodies Publications |
---|
Sep. 11 2024
NICE Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over Publication Type: Expected publication Document: Managed access agreement (PDF 447 KB) (webpage) Published Found: Subject to Notice of rights . 14 of 27 • Exposure, such as the date of the haematopoietic stem |
Sep. 11 2024
NICE Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over Publication Type: Education Document: Managed access agreement (PDF 2.7 MB) (webpage) Published Found: Subject to Notice of rights. 14 of 27 •Exposure, such as the date of the haematopoietic stem cell transplantation |
Sep. 05 2024
NICE Source Page: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115] Publication Type: Draft guidance Document: Draft guidance (downloadable version) PDF 331 KB (webpage) In consultation Found: that there is an unmet need for additional treatment options for older people who are ineligible for stem |
Sep. 05 2024
NICE Source Page: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115] Publication Type: Draft guidance Document: Committee papers PDF 8.97 MB (webpage) In consultation Found: Allogeneic stem cell transplantation for myelofibrosis patients aged >/=6 5 years. |
Sep. 05 2024
NICE Source Page: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115] Publication Type: Draft guidance Document: Public committee slides PDF 1.04 MB (webpage) In consultation Found: stakeholder highlighted unmet need for additional treatment options in older patients who are ineligible for stem |
Sep. 05 2024
NICE Source Page: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115] Publication Type: Draft guidance Document: Equality impact assessment (downloadable version) PDF 121 KB (webpage) In consultation Found: that there is an unmet need for additional treatment options for older people who are ineligible for stem |
Aug. 08 2024
NICE Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over Publication Type: Final draft guidance Document: Final draft guidance (PDF 342 KB) (webpage) Published Found: transfusion -dependent β-thalassemia in patients 12 years of age and older for whom haematopoietic stem |
Aug. 08 2024
NICE Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over Publication Type: Final draft guidance Document: Managed Access Agreement (PDF 498 KB) (webpage) Published Found: Subject to Notice of rights . 14 of 27 • Exposure, such as the date of the haematopoietic stem |
Sep. 26 2023
NICE Source Page: Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment Publication Type: Invitation to participate Document: NICE's response to comments on the draft scope and provisional stakeholder list (PDF 202 KB) (webpage) Published Found: • As highlighted in the ESMO guidelines, autologous stem cell transplantation may be considered |
Sep. 26 2023
NICE Source Page: Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment Publication Type: Invitation to participate Document: Final scope (PDF 181 KB) (webpage) Published Found: Chapter 29: Haematopoietic stem cell transplantation services (adults and children) and Chapter 105 |
Aug. 22 2023
NICE Source Page: Iptacopan for treating paroxysmal nocturnal haemoglobinuria Publication Type: Invitation to participate Document: Final scope (PDF 173 KB) (webpage) Published Found: Allogeneic stem cell transplantation may be curative but is associated with significant risks and is |
Jul. 26 2023
NICE Source Page: Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment Publication Type: Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5085 Document: Draft scope post referral (PDF 214 KB) (webpage) Published Found: Stem cell transplantation may also be considered and s plenectomy can be considered for splenic marginal |
May. 24 2023
NICE Source Page: Iptacopan for treating paroxysmal nocturnal haemoglobinuria Publication Type: Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6176 Document: Draft scope post referral (PDF 180 KB) (webpage) Published Found: Allogeneic stem cell transplantation may be curative but is associated with significant risks and is |
Apr. 25 2023
NICE Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over Publication Type: Invitation to participate Document: Draft scope and provisional stakeholder list comments table (post-referral) (PDF 770 KB) (webpage) Published Found: As such, allogenic stem cell transplantation has been removed as a comparator . |
Apr. 25 2023
NICE Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over Publication Type: Invitation to participate Document: Final scope (PDF 169 KB) (webpage) Published Found: Angelucci E, Matthes -Martin S, Baronciani D et al. (2014) Hematopoietic stem cell transplantation |
Jan. 19 2023
NICE Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over Publication Type: Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4015 Document: Draft scope post referral (PDF 172 KB) (webpage) Published Found: Angelucci E, Matthes -Martin S, Baronciani D et al. (2014) Hematopoietic stem cell transplantation |